FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer .

 

Application is Being Reviewed Under FDA's Real-Time Oncology Review Pilot Program .

• Based on results of the Phase III IMpower010 study presented at ASCO that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with best supportive care .

• Tecentriq is the first and only cancer immunotherapy to demonstrate positive Phase III results in the adjuvant lung cancer setting . ...